Patents covering drugs selected for Medicare price negotiation show how patents influence drug prices.
Marching-in could allow federal government to commercialize inventions, but at the expense of patent rights.
Supreme Court approval of patent adjudication raises new questions about limits of modern agency adjudication.
Supreme Court holds that government cannot discriminate against offensive trademarks.
Is the government willing to infringe on drug patents to curb a public health crisis?
The Supreme Court upholds its concededly “incorrect” ban on post-expiration patent royalties.
Improving the patent system depends on reducing processing snarls.
Asymmetrical deference to PTO decision-making may promote pro-patent policies.
Patent and Trademark Office proposes rule that would seek to increase transparency in patent ownership.
Proposed fee structure remains flawed and may contribute to the perception of a “broken” patent system.
Statutory change will ease medical training and health care delivery by the Department of Defense.